open access

Vol 80, No 7 (2009)
ARTICLES
Get Citation

Concentration of soluble ligand for receptor CD30 (sCD30L) – marker of apoptosis in women with ovarian tumor

Jerzy Świtała, Krzysztof Sodowski, Justyna Sikora, Zdzisława Kondera-Anasz, Aleksandra Mielczarek-Palacz, Robert Kubina
Ginekol Pol 2009;80(7).

open access

Vol 80, No 7 (2009)
ARTICLES

Abstract

Summary Objectives: Impairments of apoptosis processes are the basis of pathogenesis of many diseases, including ovarian tumors. The aim of the study was to evaluated the concentration of soluble ligand for receptor CD30 (sCD30L) – marker of apoptosis in women with ovarian tumor. Material and methods: The study comprised 80 women, aged from 21 to 62, and included 30 patients with Cystadenocarcinoma serosum Ia, 35 with Cystadenoma serosum and 15 women with Teratoma maturum. The control group consisted of 30 healthy women, aged 24 to 57, with no evidence of pathological disorders in the reproductive system. The concentration of sCD30L in the serum of all studied women and in the fluid of ovarian cyst of women with cystadenoma serous were measured by immunoenzymatic method ELISA. Results: The highest level of sCD30L was observed in the serum of women with ovarian cancer and it was significantly higher when compared to the concentration in the serum of women with cystadenoma serous and teratoma maturum of the ovary (p<0.0001). In the fluid of ovarian cyst, the concentration of this marker was significantly higher in comparison with the level in the serum (p<0.0001). Conclusions: In women with ovarian tumors we observed impairments of the apoptosis process, which is associated with an increased concentration of sCD30L in the serum. These changes are more intense in women with ovarian cancer. Higher level of the study parameter in the fluid of ovarian cyst is associated with the local immune response suppression.

Abstract

Summary Objectives: Impairments of apoptosis processes are the basis of pathogenesis of many diseases, including ovarian tumors. The aim of the study was to evaluated the concentration of soluble ligand for receptor CD30 (sCD30L) – marker of apoptosis in women with ovarian tumor. Material and methods: The study comprised 80 women, aged from 21 to 62, and included 30 patients with Cystadenocarcinoma serosum Ia, 35 with Cystadenoma serosum and 15 women with Teratoma maturum. The control group consisted of 30 healthy women, aged 24 to 57, with no evidence of pathological disorders in the reproductive system. The concentration of sCD30L in the serum of all studied women and in the fluid of ovarian cyst of women with cystadenoma serous were measured by immunoenzymatic method ELISA. Results: The highest level of sCD30L was observed in the serum of women with ovarian cancer and it was significantly higher when compared to the concentration in the serum of women with cystadenoma serous and teratoma maturum of the ovary (p<0.0001). In the fluid of ovarian cyst, the concentration of this marker was significantly higher in comparison with the level in the serum (p<0.0001). Conclusions: In women with ovarian tumors we observed impairments of the apoptosis process, which is associated with an increased concentration of sCD30L in the serum. These changes are more intense in women with ovarian cancer. Higher level of the study parameter in the fluid of ovarian cyst is associated with the local immune response suppression.
Get Citation

Keywords

apoptosis, CD30 Ligand, ovarian neoplasms

About this article
Title

Concentration of soluble ligand for receptor CD30 (sCD30L) – marker of apoptosis in women with ovarian tumor

Journal

Ginekologia Polska

Issue

Vol 80, No 7 (2009)

Bibliographic record

Ginekol Pol 2009;80(7).

Keywords

apoptosis
CD30 Ligand
ovarian neoplasms

Authors

Jerzy Świtała
Krzysztof Sodowski
Justyna Sikora
Zdzisława Kondera-Anasz
Aleksandra Mielczarek-Palacz
Robert Kubina

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl